Compare CHEF & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | TLX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2011 | N/A |
| Metric | CHEF | TLX |
|---|---|---|
| Price | $64.33 | $7.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $76.83 | $21.13 |
| AVG Volume (30 Days) | ★ 424.4K | 311.0K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | ★ $38.08 | $150.33 |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $45.00 | $6.28 |
| 52 Week High | $73.94 | $19.93 |
| Indicator | CHEF | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 57.34 |
| Support Level | $60.76 | $7.72 |
| Resistance Level | $65.47 | $8.19 |
| Average True Range (ATR) | 2.40 | 0.23 |
| MACD | -0.54 | 0.13 |
| Stochastic Oscillator | 35.43 | 84.52 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.